Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

Ultrasound-Proven Severe Synovitis Induced by PD-1 Inhibitor Therapy in a Patient Predisposed to Seronegative Inflammatory Arthritis.

Kawashiri SY, Iwamoto N, Ohba K, Kawakami A.

Case Rep Rheumatol. 2019 Jul 24;2019:7340692. doi: 10.1155/2019/7340692. eCollection 2019.

2.

Epidemiological survey and risk factor analysis of dialysis-related amyloidosis including destructive spondyloarthropathy, dialysis amyloid arthropathy, and carpal tunnel syndrome.

Tagami A, Tomita M, Adachi S, Tsuda K, Yamada S, Chiba K, Okazaki N, Yonekura A, Tsujimoto R, Kajiyama S, Matsubayashi S, Miyamoto T, Mochizuki Y, Ohba K, Osaki M.

J Bone Miner Metab. 2019 Aug 14. doi: 10.1007/s00774-019-01028-6. [Epub ahead of print]

PMID:
31414282
3.

Efficacy of Tadalafil Therapy and Changes in Oxidative Stress Levels in Male Patients with Lower Urinary Tract Symptoms and Overactive Bladder.

Matsuo T, Miyata Y, Araki K, Mukae Y, Otsubo A, Ohba K, Sakai H.

Low Urin Tract Symptoms. 2019 Aug 13. doi: 10.1111/luts.12283. [Epub ahead of print]

PMID:
31407871
4.

Periodontal Disease in Patients Receiving Dialysis.

Miyata Y, Obata Y, Mochizuki Y, Kitamura M, Mitsunari K, Matsuo T, Ohba K, Mukae H, Nishino T, Yoshimura A, Sakai H.

Int J Mol Sci. 2019 Aug 3;20(15). pii: E3805. doi: 10.3390/ijms20153805. Review.

5.

Pathological Characteristics of Periodontal Disease in Patients with Chronic Kidney Disease and Kidney Transplantation.

Kitamura M, Mochizuki Y, Miyata Y, Obata Y, Mitsunari K, Matsuo T, Ohba K, Mukae H, Yoshimura A, Nishino T, Sakai H.

Int J Mol Sci. 2019 Jul 11;20(14). pii: E3413. doi: 10.3390/ijms20143413. Review.

6.

Stage-specific embryonic antigen-4 is a histological marker reflecting the malignant behavior of prostate cancer.

Nakamura Y, Miyata Y, Matsuo T, Shida Y, Hakariya T, Ohba K, Taima T, Ito A, Suda T, Hakomori SI, Saito S, Sakai H.

Glycoconj J. 2019 Jun 26. doi: 10.1007/s10719-019-09882-2. [Epub ahead of print]

PMID:
31243630
7.

A pilot study to assess the safety and usefulness of combined transurethral endoscopic mucosal resection and en-bloc resection for non-muscle invasive bladder cancer.

Hayashida Y, Miyata Y, Matsuo T, Ohba K, Sakai H, Taba M, Naito S, Taniguchi K.

BMC Urol. 2019 Jun 24;19(1):56. doi: 10.1186/s12894-019-0486-0.

8.

A Review of Oxidative Stress and Urinary Dysfunction Caused by Bladder Outlet Obstruction and Treatments Using Antioxidants.

Miyata Y, Matsuo T, Mitsunari K, Asai A, Ohba K, Sakai H.

Antioxidants (Basel). 2019 May 15;8(5). pii: E132. doi: 10.3390/antiox8050132. Review.

9.

The Pathological Significance and Prognostic Roles of Thrombospondin-1, and -2, and 4N1K-peptide in Bladder Cancer.

Nakamura Y, Miyata Y, Takehara K, Asai A, Mitsunari K, Araki K, Matsuo T, Ohba K, Sakai H.

Anticancer Res. 2019 May;39(5):2317-2324. doi: 10.21873/anticanres.13348.

PMID:
31092423
10.

Oral Intake of Royal Jelly Has Protective Effects Against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial.

Araki K, Miyata Y, Ohba K, Nakamura Y, Matsuo T, Mochizuki Y, Sakai H.

Medicines (Basel). 2018 Dec 20;6(1). pii: E2. doi: 10.3390/medicines6010002.

11.

Anticancer Effects of Green Tea and the Underlying Molecular Mechanisms in Bladder Cancer.

Miyata Y, Matsuo T, Araki K, Nakamura Y, Sagara Y, Ohba K, Sakai H.

Medicines (Basel). 2018 Aug 10;5(3). pii: E87. doi: 10.3390/medicines5030087. Review.

12.

High Consumption of Green Tea Suppresses Urinary Tract Recurrence of Urothelial Cancer via Down-regulation of Human Antigen-R Expression in Never Smokers.

Yasuda T, Miyata Y, Nakamura Y, Sagara Y, Matsuo T, Ohba K, Sakai H.

In Vivo. 2018 Jul-Aug;32(4):721-729. doi: 10.21873/invivo.11300.

13.

Pathological significance and prognostic roles of densities of CD57+ cells, CD68+ cells, and mast cells, and their ratios in clear cell renal cell carcinoma.

Nakanishi H, Miyata Y, Mochizuki Y, Yasuda T, Nakamura Y, Araki K, Sagara Y, Matsuo T, Ohba K, Sakai H.

Hum Pathol. 2018 Sep;79:102-108. doi: 10.1016/j.humpath.2018.05.007. Epub 2018 May 19.

14.

Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.

Miyata Y, Matsuo T, Nakamura Y, Yasuda T, Ohba K, Takehara K, Sakai H.

Anticancer Res. 2018 Mar;38(3):1629-1635.

PMID:
29491095
15.

Efficacy and safety of sunitinib alternate day regimen in patients with metastatic renal cell carcinoma in Japan: Comparison with standard 4/2 schedule.

Ohba K, Miyata Y, Yasuda T, Asai A, Mitsunari K, Matsuo T, Mochizuki Y, Matsunaga N, Sakai H.

Asia Pac J Clin Oncol. 2018 Jun;14(3):153-158. doi: 10.1111/ajco.12849. Epub 2018 Jan 31.

PMID:
29383843
16.

A Mini-Review of Reactive Oxygen Species in Urological Cancer: Correlation with NADPH Oxidases, Angiogenesis, and Apoptosis.

Miyata Y, Matsuo T, Sagara Y, Ohba K, Ohyama K, Sakai H.

Int J Mol Sci. 2017 Oct 22;18(10). pii: E2214. doi: 10.3390/ijms18102214. Review.

17.

Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters.

Miyata Y, Nakamura Y, Yasuda T, Matsuo T, Ohba K, Furusato B, Fukuoka J, Sakai H.

Prostate. 2017 Oct;77(14):1408-1415. doi: 10.1002/pros.23402. Epub 2017 Aug 28.

18.

Human antigen R as a predictive marker for response to gemcitabine-based chemotherapy in advanced cisplatin-resistant urothelial cancer.

Miyata Y, Mitsunari K, Akihiro A, Watanabe SI, Matsuo T, Ohba K, Sakai H.

Oncol Lett. 2017 Feb;13(2):811-818. doi: 10.3892/ol.2016.5484. Epub 2016 Dec 12.

19.
20.

Use of Corticosteroids for Urinary Tuberculosis Patients at Risk of Developing Ureteral Obstruction.

Matsui K, Furumoto A, Ohba K, Mochizuki K, Tanaka T, Takaki M, Morimoto K, Ariyoshi K.

Intern Med. 2016;55(23):3539-3542. Epub 2016 Dec 1.

Supplemental Content

Loading ...
Support Center